Cargando…

Resistance of glioma cells to nutrient-deprived microenvironment can be enhanced by CD133-mediated autophagy

CD133 is a pentaspan transmembrane protein that can serve as a biomarker for cancer stem cells, although its biochemical mechanism remains unclear. Here we report that CD133 expression enhances glioma cell tolerance of a nutrient-deprived microenvironment. Under starvation conditions, CD133-positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Haojie, Zhang, Mingzhi, Cheng, Kai, Li, Peng, Han, Shuo, Li, Ruizhi, Su, Ming, Zeng, Wotan, Liu, Jinwen, Guo, Jinhai, Liu, Yinan, Zhang, Xiaoyan, He, Qihua, Shen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342810/
https://www.ncbi.nlm.nih.gov/pubmed/27780926
http://dx.doi.org/10.18632/oncotarget.12803
Descripción
Sumario:CD133 is a pentaspan transmembrane protein that can serve as a biomarker for cancer stem cells, although its biochemical mechanism remains unclear. Here we report that CD133 expression enhances glioma cell tolerance of a nutrient-deprived microenvironment. Under starvation conditions, CD133-positive cells exhibited higher survival and decreased levels of apoptosis. These changes were dependent on activation of autophagy-associated gene signaling and were impaired by the autophagic inhibitor chloroquine. Furthermore, rapamycin up-regulated the level of autophagy and inversely reduced CD133 expression. Immunofluorescence confirmed that starvation promoted release of CD133 from the plasma membrane to the cytoplasm, with CD133 also partially co-localizing with LC3 upon starvation. Additionally, CD133 partially co-localized with Beclin1, Atg5, and lysosomes, indicating that CD133 directly participates in the autophagosome membrane fusion process and ultimately undergoes lysosomal degradation. Collectively, our results demonstrate that CD133 contributes to cell survival by regulating autophagy, and that targeting CD133-linked signaling and autophagy may be useful in improving anti-cancer treatments.